CD274 and neoplasm: While the anti-PD1 immunotherapy response in metastatic NSCLC is heavily influenced by tumour PD-L1 expression [28, 29], in the PACIFIC trial in stage III NSCLC the benefit of 12 months durvalumab immediately following chemoradiotherapy was irrespective of baseline tumour PD-L1 expression [30].